Taroh Satoh - Concepedia

Author

Taroh Satoh

Also Known As

Hyun Cheol Chung, S. Nakamori, Satoh Taroh, T Satoh, T. SATOH, T. Satoh, T.H. Satoh, TAROH SATOH, Taroh H Satoh, Taroh Satoh

526

Publications

24.9K

Citations

H-Index

149

Concepts

All Affiliations

The University of Osaka Kindai University Aichi Cancer Center National Cancer Center Hospital East Saitama Cancer Center

About

Taroh Satoh is an author at The University of Osaka specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	35	92	16K
2	Health Sciences	14	19	1.1K
3	Engineering	5	5	766
4	Management	1	1	16
5	Public Health	1	1	23

Taroh Satoh

181

Publications

22.2K

Citations

H-Index

Page 1

	Year	Citations
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Yung‐Jue Bang, Eric Van Cutsem, A. Feyereislova, The Lancet Surgical OncologyChemotherapy Versus ChemotherapyGastrointestinal OncologyMedicineGastroenterology	2010	7.2K
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial Yoon‐Koo Kang, Narikazu Boku, Taroh Satoh, The Lancet Esophageal CancerGastrointestinal OncologyLeast TwoMedicineGastroenterology	2017	2.2K
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, The Lancet UrologySurgical OncologyGastrointestinal OncologyMedicineBiliary Cancer	2023	891
An anonymous communication technique using dummies for location-based services Hidetoshi Kido, Y. Yanagisawa, Taroh Satoh EngineeringLocation PrivacyInformation SecurityAnonymous Communication TechniqueCommunication	2005	688
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab Kimio Yonesaka, Kreshnik Zejnullahu, Isamu Okamoto, Science Translational Medicine Cetuximab SensitivityOncologyErbb2 SignalingSignaling PathwayMedicine	2011	658
Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of <i>HER2</i>-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study Taroh Satoh, Rui‐Hua Xu, Hyun Cheol Chung, Journal of Clinical Oncology	2014	611
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial Sun Young Rha, Do‐Youn Oh, Patricio Yañez, The Lancet Oncology Chemotherapy Versus PlaceboGastrointestinal OncologyMedicineClinical TrialsImmune Checkpoint Inhibitor	2023	521
Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial Toshihiro Kudo, Yasuo Hamamoto, Ken Kato, The Lancet Oncology Surgical OncologyEsophageal CancerNivolumab TreatmentGastrointestinal OncologyMedicine	2017	378
The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells Kosuke Taketo, Masamitsu Konno, Ayumu Asai, International Journal of Oncology Systems BiologyOncologyPancreatic CancerMedicineGene Expression	2017	371
Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904) Shinzoh Kudoh, Koji Takeda, Kazuhiko Nakagawa, Journal of Clinical Oncology	2006	365

Page 1